and preclinical studies show that it can penetrate and deplete CD20-expressing cells in tissues like the spleen, bone marrow, and lymph nodes. IGM-2644 or CD38 x CD3, a bispecific IgM monoclonal ...
One of these therapies, rituximab, a chimeric monoclonal antibody against human CD20 ... the spleen and lymph nodes were also found to be short-lived with a higher turnover rate than normal ...
ICP-B02 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback